Colin Graham Knox

Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom.

Oxford Science Enterprises PLC (Oxford Science Enterprises) is a venture capital firm founded in 2015. The firm is headquartered in Oxford, United Kingdom.

Galapagos Biotech Ltd. operates as a drug discovery company which provides discovery technologies and services. Its technologies include Chemogenomics and Silico. The company was founded by Kenneth Leslie Powell and Janet Maureen Thornton in July 8, 1997 and is headquartered in Cambridge, the United Kingdom.

MVM Partners LLP (MVM Partners) is a venture capital firm founded in 1997. The firm is headquartered in London, the United Kingdom.

LGC Holdings Ltd. provides chemical, DNA and other scientific analysis in areas such as drug development, health care services, chemicals & petrochemicals, law enforcement, agriculture, food production, and environmental quality & maintenance. The company was founded in February 1996 and is located in Teddington, UK.

Acacia Pharma Ltd. develops supportive care product opportunities for post-surgical and cancer patients. It specializes in the discovery and development of cancer supportive care product opportunities based on established drugs. The firm’s product pipeline addresses supportive care indications, such as post-operative and chemotherapy-induced nausea and vomiting, xerostomia and cachexia. The company was founded by Andrew Muncey, Julian Clive Gilbert and Robert William Gristwood in 2006 and is headquartered in Cambridge, the United Kingdom.

Part of Charles River Laboratories International, Inc., Cambridge Drug Discovery Holdings Ltd. is a company that researches potential new drugs for the treatment of cancer. The company is based in Cambridge, UK. Cambridge Drug Discovery Holdings was acquired by Charles River Discovery Research Services UK Ltd., part of Charles River Laboratories International, Inc. from November 14, 2005 on June 11, 2001 for $38 million. The British company was founded by Barry Kenny, Jonathan Mark Treherne.

Macrophox Ltd. engages in the provision of research and experimental development on biotechnology. The company was founded on March 12, 2018 and is headquartered in Woodstock, The United Kingdom.

Part of Aghoco (1579) Topco Ltd., Aghoco 1566 (Bidco) Ltd. functions as an investment holding British company. The company is based in Nottingham, UK.

Johnson & Johnson Innovation JJDC Inc (Johnson & Johnson Innovation JJDC) is a venture capital subsidiary of Johnson & Johnson founded in 1973. The firm is headquartered in New Brunswick, New Jersey.

Aghoco (1579) Topco Ltd. is a British biotechnology company founded in 2017. The private company is based in Nottingham, UK. and has subsidiaries in United Kingdom. Aghoco engages in research and development in biotechnology.

Part of Aghoco (1579) Topco Ltd., Evergreen Holdco 1 Ltd. operates as a holding British company with subsidiaries that engage in research and experimental development on biotechnology. The company is based in Nottingham, UK.

Part of Aghoco (1579) Topco Ltd., RenaSci Ltd. provides pharmacy consulting services. The company is based in Nottingham, UK. The British company was founded in 2001 by Sharon Crawford Cheetham, Robert Brian Jones, David John Heal.

OMass Therapeutics Ltd. develops native mass spectrometry platform The company was founded by Dame Carol Robinson and is headquartered in Oxford, the United Kingdom.

Part of Aghoco (1579) Topco Ltd., Aghoco 1578 (Midco) Ltd. operates as a holding British company whose subsidiary manufactures drugs. The company is based in Nottingham, UK and was founded in 2017.

Part of Evergreen Holdco 2 Ltd., Sygil Group Ltd. is a holding British company that provides drug discovery services. The company is based in Nottingham, UK and was founded in 2011.

Sygnature Discovery Ltd. engages in drug discovery activities. It specializes in target validation, hit identification, hit to lead, lead optimization, integrated drug discovery, and fragment based drug discovery. The company was founded by Simon Christopher Hirst in 2004 and is headquartered in Nottingham, United Kingdom.

Part of ICON plc, Medeval Group Ltd. is a British company that carries out clinical pharmacology studies on behalf of pharmaceutical and biotechnology companies. The company is based in Manchester, UK. Medeval Group was acquired by ICON plc on January 24, 2003 for $22.64 million.

Part of Interfor Corp., Adprotech Ltd. is a British pharmaceutical manufacturing company. The company is based in Royston, UK. Adprotech was acquired by EACOM Timber Corp., part of Interfor Corp. from November 23, 2021 on April 20, 2004 for $15.23 million.

Charles River Discovery Research Services UK Ltd. provides drug discovery products and services to various pharmaceutical companies. It focuses on three areas such as kinases, G-protein coupled receptors, and ion channels. The company was founded in 1997 and is headquartered in Kent, the United Kingdom.

Syncona LLP operates as a healthcare investment company. It invests in companies which focus on gene therapy, cell therapy and patient stratification technologies. The company was founded on October 19, 2012 and is headquartered in London, the United Kingdom.

Vantia Ltd. services to provide molecule agonists of vasopressin receptors. It offers healthcare improve clinical treatments through development and commercialization of innovative medicines. The company was founded by Robert Haigh and Chris Yea in 2008 and is headquartered in Southampton, the United Kingdom.

3i Plc operates as an private equity firm and provides investment advice. The company was founded on July 21, 1945 and is headquartered in London, the United Kingdom.

Cambridge Epigenetix Ltd. provides epigenetic tools. Its TrueMethyl oxidative bisulfite sequencing, a novel technology that pioneers single-base resolution sequencing of the modified bases hydroxymethyl cytosine and methylcytosine. The firm's TrueMethyl enables analysis of the DNA methylome offers basic research, pharmaceutical discovery and diagnostics and TrueMethyl can be used with methylation arrays and targeted assays. The company was founded by Shankar Balasubramanian, Michael Booth and Bobby Yerramilli-Rao in 2012 and is headquartered in Cambridge, the United Kingdom.

Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom.

Part of McKinsey & Co., Inc., McKinsey & Co., Inc. (United Kingdom) is a consulting firm that helps UK manufacturers embrace new technologies for digital transformation and leadership. The company is based in London, UK. Ruben Schaubroeck, McKinsey Digital's new lead for the UK, Belgium, and Netherlands offices, spoke with Thomas Farrar, a manager of communications in the firm's UK office, about the importance of speed and pace for CEOs in this new growth journey. The British company works with organizations that pursue sustainability, inclusion, and economic growth, all at the same time, to achieve strategic foresight and built-in agility in the face of the COVID-19 pandemic and the new trading relationship with the EU.

Oxxon Therapeutics, Inc. develops and manufactures antigen-specific immunotherapies to treat patients with chronic infectious diseases and cancer. The company has three development programs in hepatitis, melanoma, and HIV. Oxxon Therapeutics was founded in 1999 by Dr. Joerg Schneider and is located at Oxford, UK.